Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Liquid Biopsy Falls Short for Isolated Brain Lesions in Lung Cancer

Publish date:: May 21, 2019

Key clinical point: Plasma circulating tumor DNA (ctDNA) analysis appears inadequate to detect molecular aberrations in patients with non–small cell lung cancer (NSCLC) who have isolated central nervous system (CNS) progression.

Major finding: In patients with at least 1 known NSCLC molecular alteration, ctDNA analysis was positive in 38% of those with isolated CNS disease, compared with 98% of those with systemic disease progression (P less than .0001).

Study details: A retrospective analysis of 66 patients with NSCLC, drawn from a screened population of 959 patients.

Disclosures: The investigators disclosed financial relationships with Celgene, Daiichi Sankyo, Eli Lilly, and others.

Citation:

Aldea et al. ELCC 2019. Abstract 110O.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,